Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled ‘New Vistas in Opioid Pharmacology’.
Bibliographical noteFunding Information:
Dr. Pravetoni is the inventor of “Cytokine Signaling Immunomodulators and Methods”. U.S. Provisional Patent Application No. 62/334, 167 filed on May 10, 2016. International Application No. PCT/US2017/031907 filed on May 10, 2017. In the past 36 months, Dr. Comer has served on advisory boards, received grant funding from, collaborated with, and/or consulted for: Alkermes, Braeburn, Cerecor, Charleston Labs, Clinilabs, Collegium, Corbus, Daiichi Sankyo, Depomed, Egalet, Endo, Epiodyne, Indivior, Go Medical, Inspirion Delivery Sciences, Intracellular Therapies, Janssen, KemPharm, Kures, Lyndra, Mallinckrodt, Nektar, Neurolixis, Newron, Opiant, Otsuka, Pfizer, Shin Nippon Biomedical Laboratories, and Sun Pharma. She also has received honoraria from the World Health Organization (WHO).
The authors thank the National Institute of Health for support under DA038876 (Marco Pravetoni), DA041730 (Marco Pravetoni), U54DA037842 (Sandra Comer), R01DA035207 (Sandra Comer). The authors thank Dr. Carly Baehr for comments.
- Opioid epidemic